TDOC still grinding (testing 200 day MA).  Citron still aiding 

Teladoc (TDOC)is a left-for-dead telemedicine company that spent significant capital during the “boom” years investing in a platform that now has significant competitive advantages TDOC is using AI to reduce costs and reinvesting into expanded offerings, such as their recent acquisition of Catapult Health, and I think the business is positioned to accelerate materially from here.  – unlike many “live the dream” healthcare and technology stocks from the 2021-era – TDOC is actually profitable.  The acquisition of Catapult Health strengthens Teladoc's position in the AI-enabled healthcare landscape by significantly furthering its Integrated Care game plan.  Through VirtualCheckup's sophisticated at-home diagnostic testing and virtual care platform, Teladoc gains access to rich longitudinal health data from over three million covered lives, with nearly 50% of patients having identifiable chronic conditions – precisely the type of structured healthcare data that AI systems can leverage for personalized care recommendations. The design element is enhanced through Catapult's highly engaging user experience (demonstrated by an 81+ NPS) and proven clinical outcomes, including a 77% reduction in crisis-level hypertension and 56% improvement in medication compliance, while the distribution advantage is amplified by cross-selling opportunities across Teladoc's 93.9 million US integrated care members. This consolidation of preventative care capabilities positions Teladoc to better harness AI for proactive health interventions, as evidenced by its ability to identify pre-diabetes in 28% of members for the first time, making it a more compelling play on AI enablementin healthcare while delivering tangible ROI and $1,400 in verified cost savings per member over three years.